TY - JOUR
T1 - Cationic biaryl 1,2,3-triazolyl peptidomimetic amphiphiles
T2 - synthesis, antibacterial evaluation and preliminary mechanism of action studies
AU - Tague, Andrew J.
AU - Putsathit, Papanin
AU - Hammer, Katherine A.
AU - Wales, Steven M.
AU - Knight, Daniel R.
AU - Riley, Thomas V.
AU - Keller, Paul A.
AU - Pyne, Stephen G.
PY - 2019/4/15
Y1 - 2019/4/15
N2 - Synthetic small molecular antimicrobial peptidomimetics represent a promising new class of potential antibiotics due to their membrane-disrupting ability and their decreased propensity for bacterial resistance. A library of 43 mono- and di-cationic biaryl 1,2,3-triazolyl peptidomimetics was designed and synthesized based upon previously established lead biarylpeptidomimetics and a known pharmaco-phore. A reliable, facile and modular synthetic pathway allowed for the efficient synthesis of multiple unique scaffolds which were subjected to divergent derivatization to furnish the amphiphilic compounds. In vitro testing revealed enhanced antibacterial efficacy against a range of pathogenic bacteria, including bacterial isolates with methicillin, vancomycin, daptomycin, or multi-drug resistance. Preliminary time-kill kinetics and membrane-disruption assays revealed a likely membrane-active mechanism for the tested peptidomimetics. An optimal balance between hydrophobicity and cationic charge was found to be essential for reduced cytotoxicity/haemolysis (i.e. membrane selectivity) and enhanced Gram-negative activity. The cationic biaryl amphiphile 81 was identified as a potent, broad-spectrum peptidomimetic with activity against Gram-positive (methicillin-resistant Staphylococcus aureus MIC = 2 mu g/mL) and Gram-negative (Escherichia coli - MIC = 4 mu g/mL) pathogenic bacteria. (C) 2019 Elsevier Masson SAS. All rights reserved.
AB - Synthetic small molecular antimicrobial peptidomimetics represent a promising new class of potential antibiotics due to their membrane-disrupting ability and their decreased propensity for bacterial resistance. A library of 43 mono- and di-cationic biaryl 1,2,3-triazolyl peptidomimetics was designed and synthesized based upon previously established lead biarylpeptidomimetics and a known pharmaco-phore. A reliable, facile and modular synthetic pathway allowed for the efficient synthesis of multiple unique scaffolds which were subjected to divergent derivatization to furnish the amphiphilic compounds. In vitro testing revealed enhanced antibacterial efficacy against a range of pathogenic bacteria, including bacterial isolates with methicillin, vancomycin, daptomycin, or multi-drug resistance. Preliminary time-kill kinetics and membrane-disruption assays revealed a likely membrane-active mechanism for the tested peptidomimetics. An optimal balance between hydrophobicity and cationic charge was found to be essential for reduced cytotoxicity/haemolysis (i.e. membrane selectivity) and enhanced Gram-negative activity. The cationic biaryl amphiphile 81 was identified as a potent, broad-spectrum peptidomimetic with activity against Gram-positive (methicillin-resistant Staphylococcus aureus MIC = 2 mu g/mL) and Gram-negative (Escherichia coli - MIC = 4 mu g/mL) pathogenic bacteria. (C) 2019 Elsevier Masson SAS. All rights reserved.
KW - Antibacterial
KW - Peptidomimetic
KW - Biaryl cationic amphiphiles
KW - Membrane depolarization
KW - Amphipathic
KW - AZIDE-ALKYNE CYCLOADDITION
KW - ANTIMICROBIAL PEPTIDOMIMETICS
KW - RESISTANCE
KW - MIMICS
UR - http://www.scopus.com/inward/record.url?scp=85062208426&partnerID=8YFLogxK
U2 - 10.1016/j.ejmech.2019.02.013
DO - 10.1016/j.ejmech.2019.02.013
M3 - Article
C2 - 30831407
VL - 168
SP - 386
EP - 404
JO - European Journal of Medicinal Chemistry
JF - European Journal of Medicinal Chemistry
SN - 0223-5234
ER -